PHARMA MAR, S.A. «12» Página 1 de 2 desde 10/10/2017 hasta 18/01/2018 18/01/2018 19:00 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks CORAIL Phase III with Zepsire in resistant ovarian cancer has not met its primary endpoint. Número de registro: 260786 11/01/2018 17:58 PHARMA MAR, S.A. Liquidity contracts and specialists The Company reports details of the operations of the Liquidity Agreement between 11/10/2017 and 10/01/2018 Número de registro: 260607 09/01/2018 14:13 PHARMA MAR, S.A. Strategic plans, profit forecasts and presentations New corporate presentation (English version) which will be available in the Company´s web site. Número de registro: 260513 03/01/2018 09:24 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks In relation to the Significant Fact n. 259611, PharmaMar has requested from the European Medicines Agency the re-examination of the negative Opinion issued by the CHMP for Aplidin® for the indication of relapsed and refractory multiple myeloma. Número de registro: 260272 15/12/2017 12:43 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks In relation to the Significant Fact n. 258359, the CHMP of EMA has finally emitted its opinion against the approval of Aplidin® in multiple myeloma. Número de registro: 259611 11/12/2017 08:18 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks In relation to Significant Fact n 236.798, presentation of results from ADMYRE Phase III trial of plitidepsin in multiple myeloma at the 59th American Society of Hematology annual Meeting & Exposition. Número de registro: 259246 15/11/2017 08:12 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks After analysis of the safety data of the first 150 patients, IDMC recommends that the Phase III trial with Zepsyre® in small-cell lung cancer patients should continue without any changes Número de registro: 258531 14/11/2017 08:09 PHARMA MAR, S.A. Announcements of public presentations and meetings Pharma Mar will participate in the Stifel Nicolaus Weisel Healthcare Conference to be held in New York on Nov. 15. Número de registro: 258469 08/11/2017 19:31 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks Pharma Mar announces CHMP negative trend vote in relation to Aplidin Marketing Authorization Application for multiple myeloma. Número de registro: 258359 24/10/2017 17:49 PHARMA MAR, S.A. Information on P&L The Company sends press release regarding the third quarter 2017 results. Número de registro: 257730 Página 1 de 2 «12»